SEP 8, 2026 · JOURNAL ARTICLE
Safety, Pharmacokinetics and Pharmacodynamics of the GLP ‐1/ GIP / GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo‐Controlled Phase 1a/1b Study
Diabetes Obesity and Metabolism
First-in-human Phase 1a/1b trial with primary endpoints of safety and tolerability; pharmacodynamic weight loss and metabolic findings are encouraging but uncontrolled comparisons in a small, early-phase study cannot yet support practice changes.
Reported
Body weight reduction (UBT251 1–6…8.96–13.48 kg
Body weight change (placebo, 12 w…1.57 kg increase
Dose range for linear pharmacokin…1.0–6.0 mg